1451 related articles for article (PubMed ID: 24782282)
1. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Hasegawa T; Nishiwaki H; Ota E; Levack WM; Noma H
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013109. PubMed ID: 33586138
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Cooper TE; Teng C; Tunnicliffe DJ; Cashmore BA; Strippoli GF
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD007751. PubMed ID: 37466151
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
[TBL] [Abstract][Full Text] [Related]
7. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
8. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.
Natale P; Palmer SC; Navaneethan SD; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2024 Apr; 4(4):CD006257. PubMed ID: 38682786
[TBL] [Abstract][Full Text] [Related]
10. Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
Bolignano D; Palmer SC; Ruospo M; Zoccali C; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010294. PubMed ID: 26171904
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive agents for preventing diabetic kidney disease.
Lv J; Perkovic V; Foote CV; Craig ME; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2012 Dec; 12():CD004136. PubMed ID: 23235603
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
Zhang L; Zeng X; Fu P; Wu HM
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological interventions for heart failure in people with chronic kidney disease.
Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
An J; Niu F; Sim JJ
Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
[TBL] [Abstract][Full Text] [Related]
17. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
[TBL] [Abstract][Full Text] [Related]
18. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Carpenter A; Dale-Harris I; Dorée C; Estcourt LJ
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012380. PubMed ID: 37539955
[TBL] [Abstract][Full Text] [Related]
19. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
[TBL] [Abstract][Full Text] [Related]
20. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
